Actinium Pharmaceuticals to Present ATNM-400 at Breast Cancer Symposium
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) is set to reveal important preclinical data at the upcoming San Antonio Breast Cancer Symposium. This data underscores the anti-tumor activity of ATNM-400, particularly within hormone-resistant and HER2-resistant breast cancer sectors, highlighting a crucial need for innovative treatments that overcome current limitations of tamoxifen and trastuzumab.
New Findings on ATNM-400's Efficacy
ATNM-400 is designed to bring significant advancements across various malignancies—it exhibits efficacy not only against breast cancer but also prostate cancer and non-small cell lung cancer (NSCLC). This offers hope for patients who have not responded to existing therapies, enhancing the landscape of cancer care.
Key Data Presentation at SABCS
The presentation at the San Antonio Breast Cancer Symposium will occur on December 11, around the evening session. It will delve into the impressive results of ATNM-400, a first-in-class antibody radioconjugate utilizing Actinium-225 (Ac-225). This therapy directly targets cancer cells, paving the way for effective treatments especially for those with a history of resistance to standard therapies.
Insights from Preclinical Studies
Preclinical studies reveal that ATNM-400 excels in delivering alpha-particle radiation specifically to tumor cells. This approach allows for effective cancer cell destruction while minimizing damage to surrounding healthy tissues. The research specifically indicates its ability to synergize with existing therapies, positioning it as a robust candidate for both monotherapy and combination treatments.
Prostate Cancer Highlights
Data has shown ATNM-400's exceptional performance in prostate cancer settings, showcasing a substantial improvement in efficacy compared to traditional therapies. It provides long-lasting tumor control and demonstrates synergy with other treatments, particularly for patients who do not respond to standard-of-care options.
NSCLC Breakthroughs
In NSCLC, ATNM-400 has been reported to outperform other front-line therapies significantly. The combination with osimertinib, a recognized EGFR tyrosine kinase inhibitor, has resulted in impressive response rates. Such findings are crucial, given the ongoing battle against lung cancer, which absorbs a large portion of healthcare resources.
Actinium Pharmaceuticals aims to tap into the unmet needs of these significant cancer markets, compiling robust evidence to advocate for the potential of ATNM-400 across these solid tumors.
Industry Expert Comment
Sandesh Seth, the Chairman and CEO of Actinium Pharmaceuticals, expressed enthusiasm about the upcoming presentation, noting how ATNM-400 has the potential to drastically alter treatment outcomes for patients.Seth emphasized the transformative capabilities of this therapy across various malignancies, showcasing a strategic emphasis on precision therapy in the oncological arena.
About Actinium Pharmaceuticals, Inc.
Actinium is at the forefront of the integration of targeted radiotherapies intended to improve patient outcomes. With a focus on solid tumor indications, including prostate cancer, NSCLC, and breast cancer, the company strives to innovate the approach to cancer treatment. The data being presented at the symposium is just a glimpse of Actinium's broader goals in medical research and development.
Frequently Asked Questions
What is ATNM-400?
ATNM-400 is an innovative antibody-radioconjugate powered by Actinium-225, targeting tumor cells to deliver effective radiotherapy.
Where will ATNM-400 be presented?
The data for ATNM-400 will be showcased at the San Antonio Breast Cancer Symposium.
What are the primary cancers ATNM-400 targets?
ATNM-400 targets prostate cancer, non-small cell lung cancer, and breast cancer, making it a multi-indication candidate.
Who is developing ATNM-400?
Actinium Pharmaceuticals, Inc. is the developer of ATNM-400, focusing on advancements in targeted cancer therapies.
What potential does ATNM-400 have in cancer treatment?
ATNM-400 shows promise in overcoming resistance to standard therapies and may lead to improved outcomes for patients with challenging cancer types.
